- Home
- SOPH vs AVIR Comparison
SOPH vs AVIR Comparison
Compare SOPH & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SOPH | AVIR |
|---|---|---|
| Founded | 2011 | 2012 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 462.3M | 429.1M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SOPH | AVIR |
|---|---|---|
| Price | $8.21 | $5.81 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 1 |
| Target Price | $7.50 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 549.7K | 219.5K |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $351,367,000.00 |
| Revenue This Year | $23.09 | N/A |
| Revenue Next Year | $19.57 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.10 | $2.78 |
| 52 Week High | $8.98 | $6.45 |
Technical Indicators
Market Signals| Indicator | SOPH | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 57.63 | 67.78 |
| Support Level | $4.57 | $5.13 |
| Resistance Level | $8.98 | $6.37 |
| Average True Range (ATR) | 0.50 | 0.22 |
| MACD | -0.08 | 0.02 |
| Stochastic Oscillator | 48.10 | 93.38 |
Price Performance
Historical ComparisonAbout SOPH SOPHiA GENETICS SA
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.